Obesity drugs news, events & figures

FDA proposal would curb bulk compounding of Novo, Lilly weight-loss drugs

The FDA proposal could limit bulk compounding of key Novo Nordisk and Eli Lilly obesity and diabetes drugs unless they return to the shortage list.